Related Experiment Videos
Agranulocytosis during clozapine therapy
Péter Gaszner1, Zoltán Makkos, Piroska Kosza
1National Institute of Psychiatry and Neurology, Budapest, Hungary.
Summary
Clozapine, an antipsychotic, can cause dangerous granulocytopenia and agranulocytosis. Early detection and treatment of these clozapine adverse effects led to full recovery in two patients.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Clozapine is an atypical antipsychotic used for psychiatric conditions.
- Granulocytopenia and agranulocytosis are known severe adverse effects of clozapine treatment.
Observation:
- A 15-year study at the National Institute of Psychiatry and Neurology in Budapest monitored 750 patients receiving clozapine.
- Seven patients developed granulocytopenia, and two developed agranulocytosis.
Findings:
- A 42-year-old female with schizoaffective psychosis developed agranulocytosis after 2 months on 400 mg/day clozapine.
- A 35-year-old male with paranoid schizophrenia developed agranulocytosis after 6 weeks on 225 mg/day clozapine.
Implications:
- These cases highlight the importance of vigilant monitoring for clozapine-induced hematological adverse effects.
- Early recognition and prompt intervention for agranulocytosis can lead to complete patient recovery.